



A/H1N1 Influenza Vaccine (Unadjuvanted) Clinical Formulation {A/California/7/2009 (H1N1)v-like virus} Split Virus, Inactivated Supplier: GlaxoSmithKline	
INDICATIONS	(1) Pregnant women at any stage of pregnancy ^❶ (2) Healthy children and adults 10-64 years of age ^❷ (3) By parental request only for children 3-9 years of age ^❸
DOSAGE	(1)& (2) One dose 0.5 ml IM (3) 2 doses of 0.5 ml IM (21 days apart)
CONTRA-INDICATIONS	1. History of anaphylactic reaction to a previous dose of influenza vaccine or to any component of this vaccine 2. History of anaphylactic reaction to eggs 3. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a previous dose of influenza vaccine 4. History of severe oculorespiratory syndrome (ORS) that resulted in hospitalization following receipt of influenza vaccine.
VACCINE COMPONENTS	15 µg HA - A/California/7/2009(H1N1)v-like strain, sodium chloride, potassium chloride, sodium phosphate dibasic heptahydrate, potassium phosphate monobasic, thimerosal ^❹ (10 µg per 0.5 mL dose), trace residual amounts of egg proteins, formaldehyde, sodium deoxycholate and sucrose.
ADVERSE EVENTS	Local: pain, redness and swelling, Systemic: myalgia, fever, headache, malaise Events occur with a frequency similar to seasonal influenza vaccines.
SPECIAL CONSIDERATIONS	Vaccine is a translucent to whitish opalescent suspension that may sediment slightly. Inspect for discoloration prior to administration. If this condition exists, do not administer the vaccine. Shake the multidose vial vigorously each time before withdrawing a dose of vaccine. Use vaccine vial contents within 28 days of first puncture.
^❶ Offer unadjuvanted A/H1N1 vaccine preferentially to adjuvanted vaccine to pregnant women at any time during pregnancy. ^❷ Sufficient quantities of nonadjuvanted vaccine should be held in reserve to meet pregnancy indication needs in each health authority until influenza vaccine for 2010-11 is available. Use for the 10-64 indication should take this supply issue into account. ^❸ The recommended vaccine for children 3-9 years of age is the adjuvanted H1N1 vaccine. ^❹ Large-scale studies have shown no association between childhood vaccination with thimerosal-containing vaccines and neurodevelopmental outcomes, including autistic spectrum disorders. There is insufficient evidence related to administration of thimerosal containing vaccines in pregnancy. Any risk, if at all, is theoretical.	

A/H1N1 Influenza Vaccine Instructional Materials for Health Professionals are available at:
<http://www.immunizebc.ca/ImmForHP/H1N1.htm>